Nikolay Turovets, Ph.D., is the CEO at DefenAge/Progenitor Biologics LLC (PB),
a California-based regenerative medicine company. Before joining PB, Nikolay
was a part of an executive team at UC Irvine to develop the first stem cell-based
therapy to cure retinitis pigmentosa (US FDA-cleared Phase 2b was initiated in
2017; RMAT designation). Prior to joining UC Irvine, Dr. Turovets served on the
International Stem Cell Corporation as Director of Research and Therapeutic
Development where he led the company’s efforts to develop novel stem cell-
therapy drugs and oversaw the GMP manufacturing of the UniStem Cell Bank.
Dr. Turovets is a key member of the first team that intentionally derived novel
stem cell type from unfertilized human egg and created the world's largest
collection of human pluripotent parthenogenetic stem cell lines (2008). Dr.
Turovets is a primary inventor of multiple stem cell technologies including
DefenAge’s core technology.